Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), comprising approximately one-third of all cases of NHL. 1 Although the addition of rituximab to conventional chemotherapy has improved the outcomes for patients with DLBCL, a significant number still relapse and eventually die from lymphoma. 2 For patients with chemosensitive relapsed DLBCL autologous stem cell transplantation (auto-SCT) provides better outcomes than chemotherapy alone, with~50% of patients able to achieve long-term diseasefree survival. 3, 4 However, the outcomes are worse for patients with chemoresistant or high-risk disease. This includes patients with early relapse, defined as relapse less than 1 year after the date of diagnosis, primary induction failure (PIF), defined as less than complete response to first-line chemotherapy, and/or relapse after rituximab.
High-risk patients may benefit from allogeneic SCT (allo-SCT) as it provides a tumor-free source of stem cells and the potential benefit of a graft versus lymphoma (GVL) effect. Two larger retrospective studies comparing allo-SCT and auto-SCT for relapsed DLBCL showed higher non-relapse mortality (NRM) and similar OS and disease-free survival (DFS) in allo-SCT recipients, but these studies did not focus on patients with refractory disease and early relapses. 5, 6 Here, for the first time we compare the clinical outcomes of patients with early relapsed and PIF DLBCL undergoing allo-SCT vs auto-SCT.
The Washington University School of Medicine transplant database was searched to identify patients with DLBCL who had undergone auto-SCT or allo-SCT for early relapse or primary induction failure between 1 January 1997 and 30 December 2010. The final study cohort was 121 patients (42 allo-SCT, 79 auto-SCT). Patient, disease and transplant characteristics are summarized in Table 1 . The allo-SCT group was younger, more likely to have a transplant before 2003, included a higher proportion of patients with PIF and chemoresistant disease at the time of transplant, and received more chemotherapy regimens before transplant. Notably, there were no differences in stage at diagnosis, B symptoms, co-morbidity index, rituximab exposure or time from diagnosis to transplant.
The maximal response to SCT was not significantly different between auto-(63% CR, 6% PR, 4% stable disease, 17% progressive disease, 10% unknown) and allo-SCT (52% CR, 3% PR, 7% stable disease, 24% progressive disease, 14% unknown) (P = 0.53). OS at 1, 3 and 5 years after transplant was 40%, 26% and 23%, respectively, after allo-SCT and 67%, 54% and 50%, respectively, after auto-SCT (P = 0.002). In multivariate analysis, allo-SCT, age 450 years and chemoresistance at the time of transplant were associated with lower survival (Table 2) . PFS at 1, 3 and 5 years after transplant was 36%, 23% and 20%, respectively, in allo-SCT and 62%, 53% and 49%, respectively, after auto-SCT (P = 0.02). In multivariate analysis, PFS was adversely influenced by allo-SCT, age 450 years and three or more prior chemotherapy regimens ( Table 2 ). The cumulative incidence of relapse/progression was not different in the allo-SCT group compared with the auto-SCT group. At 1, 3 and 5 years after transplant, the cumulative incidence of relapse/progression was 37%, 41% and 41%, respectively, in the allo-SCT group, and 33%, 37% and 39%, respectively, in the auto-SCT group (P = 0.59). In multivariate analysis only refractory disease at transplant and longer interval between the dates of diagnosis and transplant were associated with greater risk of relapse/progression ( Table 2 ). The cumulative incidence of NRM at 1, 3 and 5 years after transplant was 40%, 56% and 60%, respectively, in allo-SCT and 9%, 17% and 20%, respectively, in auto-SCT (P = 0.0002). In multivariate analysis, only type of transplant independently predicted NRM (Table 2) .
Multiple studies have found that early relapse predicts worse outcomes for DLBCL. 3, 7, 8 In the phase III CORAL trial, patients with early relapsed DLBCL had half the response rate to salvage chemotherapy, were much less likely to proceed to auto-SCT, and had lower PFS than those who relapsed more than 12 months after the date of diagnosis.
3 For patients who do undergo auto-SCT, early relapse is a negative predictor of both OS and PFS. Allogeneic SCT for early relapse is largely understudied, but it is associated with a high risk of relapse post transplant for patients with NHL. 10 Our study is the first to focus on auto-and allo-SCT for early relapsed/PIF DLBCL. Overall, our study shows that for a combined group of DLBCL patients who do not achieve CR with first-line chemotherapy and patients who relapse early after achieving CR, auto-SCT compared to allo-SCT is associated with better OS, PFS and NRM and a similar relapse rate. These results are similar to the retrospective registry study performed by Lazarus et al. 6 despite variation in the two study populations. Compared to our study, the Lazarus study included patients with late relapses, had a lower percentage of patients with PIF and fewer patients with progressive disease during first-line chemotherapy. Despite greater chemoresistance among patients receiving allo-SCT (15% auto vs 33% allo), the incidence of relapse/progression was not different and the auto-SCT group was more likely to die of lymphoma (61% vs 35%). While this difference might be reflective of a GVL effect, it is offset by significantly higher NRM in the early post-transplant period. Of note, nearly all of the allo-SCT patients in our study were treated with myeloablative conditioning regimens. Reduced intensity conditioning (RIC) or non-myeloablative conditioning regimens have been shown to reduce NRM, but at a greater risk of relapse.
Comparison of RIC allo-SCT and auto-SCT for DLBCL with PIF or early relapse is best addressed by a prospective randomized trial.
In summary, our study suggests that while allo-SCT could be considered in patients with DLBCL with early relapse or refractory disease, auto-SCT is associated with better survival and is generally preferable. It is possible that some subsets of early-relapse patients benefit from the allo-SCT. A comparison of auto-and allo-SCT for early relapsed chemosensitive DLBCL with particular attention to various patient and disease characteristics deserves further analysis in a randomized clinical trial. Abbreviations: CIR = cumulative incidence of relapse/progression; NRM = non-relapse mortality; PFS = progression-free survival. Reference groups are allo-SCT, age ⩽ 50 years, sensitive disease and one prior chemoregimen.
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